Allergy vaccines - New approaches to an old concept

Expert Opinion on Biological Therapy

Volumn 4, Issue 9, 2004, Pages 1473-1481

  Wheeler, Alan W ^a   Woroniecki, Stefan R ^a  

^a Allergy Therapeutics Ltd   (United Kingdom)

Author keywords

Allergy vaccines; Alum; Blocking antibody; CpG; IFN ; IgE; IgG; IL 4; IL 5; ISS; Monophosphoryl lipid A; Notch receptors; T reg; Th1; Th2; Toll like receptors; Tyrosine

Indexed keywords

ADJUVANT; ALLERGEN; ALLERGY VACCINE; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; BACTERIAL DNA; CYTOKINE; DIPHTHERIA TOXOID; GAMMA INTERFERON; GLUTARALDEHYDE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; LIPOSOME; MICROSPHERE; MONOPHENOL MONOOXYGENASE; MPL; MUTEIN; NOTCH RECEPTOR; PHOSPHORYL LIPID A; POLLEN ANTIGEN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGY; ALLERGY VACCINATION; ANIMAL MODEL; CLONAL ANERGY; CPG ISLAND; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOUSE; MYCOBACTERIUM VACCAE; NONHUMAN; PARTICULATE MATTER; PEPTIDE SYNTHESIS; REVIEW; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; CPG ISLANDS; DELAYED-ACTION PREPARATIONS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOLOGIC FACTORS; LIPID A; MEMBRANE PROTEINS; RECEPTORS, NOTCH; RHINITIS, ALLERGIC, SEASONAL; TH1 CELLS; TH2 CELLS;

ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM VACCAE;

EID: 4544313426     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.9.1473     Document Type: Review

References (41)

1. RING J, KRÄMER U, SCHÄFER T et al.: Why are allergies increasing? Curr. Opin. Immunol. (2001) 13(6):701-708. An objective discussion of the various hypotheses and forms of evidence as explanations for the present worldwide explosion in allergy.
2. PORTENGEN L, SIGSGAARD T, OMLAND O, HJORT C, HEEDERIK D, DOEKES G: Low prevalence of atopy in young Danish farmers and farming students born and raised on a farm. Clin. Exp. Allergy (2002) 32(2):247-253. This paper endorses earlier studies regarding the 'protective effect' of a farm environment for the development of allergies.
3. MATRICARDI PM, RONCHETTI R: Are infections protecting from atopy? Curr. Opin. Allergy Clin. Immunol. (2001) 1(5):413-419. Provides additional support for the hygiene hypothesis of allergy.
4. CURTIS HH: The immunising cure of hay fever. Medical News. New York, USA (1900) 77:16.
5. NOON L: Prophylactic inoculation against hay fever. Lancet (1911) 1:1572.
6. GLENNY AT, POPE CG, WADDINGTON H et al.: The antigenic value of toxoid precipitated by potassium alum. J. Path. Bact. (1926) 29:38.
7. SLEDGE RF: Treatment of hay-fever with alum-precipitated pollen. US Naval Med. Bull. (1938) 36:18. The first use of an adjuvant for AV.
8. WHEELER AW, WORONIECKI SR: Immunological adjuvants in allergy vaccines: past, present and future. Allergol. Int. (2001) 50:295-301.
9. ULANOVA M, TARKOWSKI A, HAHN-ZORIC M et al.: The common vaccine adjuvant aluminium hydroxide upregulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. (2001) 69(2):1151-1159.
10. DURHAM SR, TILL SJ: Immunologic changes associated with allergen immunotherapy. J. Allergy Clin. Immunol. (1998) 102:157-164. This paper illustrated the importance of the Th2 to Th1 switch in AV.
11. AKDIS CA, BLASER K: Mechanisms of allergen-specific immunotherapy. Allergy (2000) 55:522-530.
12. MOTHES N, HEINZKILL M, DRACHENBERG KJ et al.: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy (2003) 33:1198-1208. Resurrection of the blocking antibody theory.
13. WACHHOLZ PA, DURHAM SR: Induction of 'blocking' IgG antibodies during immunotherapy. Clin. Exp. Allergy (2003) 33:1171-1174.
14. KERSTEN GF, CROMMELIN DJ: Liposomes and ISCOMS. Vaccine (2003) 21 (9-10):915-920.
15. ALVAREZ MJ, ECHECHIPIA S, GARCIA B et al.: Liposome-entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1-year double-blind, placebo-controlled trial on inflammation, bronchial hyper responsiveness and immediate and late bronchial responses to the allergen. Clin. Exp. Allergy (2002) 32(11):1574-1582.
16. SHARIF S, WHEELER AW, O'HAGAN DT: Biodegradable microparticles as a delivery system for the allergens of Dermatophagoides pteronysssinus (house dust mite): 1. Preparation and characterization of microparticles. Int. J. Pharm. (1995) 119:239-246.
17. MARSH DG: Preparation and properties of 'allergoids' derived from native pollen allergens by mild formalin treatment. Int. Arch. Allergy Appl. Immunol. (1971) 4(1):199-215. The first attempt to produce newer and safer forms of allergens, termed allergoids, by chemical modification.
18. PATTERSON R, SUSZKO IM, PRUZANSKY JJ et al.: Polymerization of mixtures of grass allergens. J. Allergy Clin. Immunol. (1977) 59(4):314-319.
19. JOHANSSON SG, MILLER AC, MULLAN N, OVERELL BG, TEES EC, WHEELER AW: Glutaraldehyde-pollen-tyrosine: clinical and immunological studies. Clin. Allergy (1974) 4(3):255-263.
20. WESTRITSCHNIG K, VALENTA R: Can we genetically engineer safer and more effective immunotherapy reagents? Curr. Opin. Allergy Clin. Immunol. (2003) 3(6):495-500.
21. SWOBODA I, JILEK A, FERREIRA F et al.: Isoforms of Bet v 1, the major birch pollen allergen, analysed by liquid chromatography, mass spectrometry, and cDNA cloning. J. Biol. Chem (1995) 2,70(6):2607-2613.
22. MAHLER V, VRTLA S, KUSS O et al.: Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin. Exp. Allergy (2004) 34(1):115-122. An interesting and scientifically elegant approach to AV.
23. NORMAN PS, OHMAN JL, LONG AA et al.: Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. (1996) 154:1623-1628. Early studies on peptides for immunotherapy.
24. LARCHE M: New approaches to immunotherapy: allergen-derived peptides. Immunol. Allergy (CPD Bulletin) (2004) 3(3):73-76. A short but useful review on T cell-reactive peptides in immunotherapy.
25. MUELLER U, AKDIS CA, FRICKER M et al.: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. (1998) 101:747-754. A study supporting the use of non-IgE-reactive T cell epitope-containing peptides for vaccination.
26. RAZ E, SPIEGELBERG HL: Deviation of the allergic IgE to an IgG response by gene immunotherapy. Int. Rev. Immunol. (1999) 18:271-289.
27. TIGH H, TAKABAYASHI K, SCHWARTZ D et al.: Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. (2000) 106:124-134.
28. KOHAMA Y, AKIZUKI O, HAGIKARI K, YAMADA E, YAMAMOTO H: Immunostimulatory oligodeoxynucleotide induces Th1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. J. Allergy Clin. Immunol. (1999) 104:1231-1238. Interesting studies of the Th1-inducing properties of bacterial ISSs.
29. WALKER C, SAWICKA E, ROOK GA: Immunotherapy with mycobacteria. Curr. Opin. Allergy Clin. Immunol. (2003) 3:481-486.
30. ULRICH JT, MYERS KR: Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: Vaccine designs. The sub-unit and adjuvant approach. Powell MF, Mewman MJ (Eds), Plenum Press, New York, USA (1995):495-524. An important review of the production and properties of a clinically acceptable Th1 adjuvant.
31. MARTIN M, MICHALEK SM, KATZ J: Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun. (2003) 71(5):2498-2507. This paper details evidence for cellular mechanisms (including activation of TLR2 and TLR4) by which MPL induces host cell activation.
32. WHEELER AW, MARSHALL JS, ULRICH JT: A Th1-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. (2001) 126:135-139. This is an interesting study showing that tyrosine and MPL can act synergistically to produce a Th1 response with model antigens.
33. DRACHENBERG KJ, WHEELER AW, STUEBNER P, HORAK F: A well-tolerated grass pollen specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseason injections. Allergy (2001) 56:498-505. A very important clinical study showing how incorporation of a Th1 adjuvant can reduce the number of injections required to obtain efficacy.
34. DRACHENBERG KJ, HEINZKILL M, URBAN E, WORONIECKI SR: Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvant by monophosphoryl lipid A (MPL®) for children and adolescents. Allergol. Immunopathol. (2003) 31(5):270-277. Confirmation of the efficacy and safety of a Th1 adjuvanted allergy vaccine. AV may reduce the progression of allergic disease in children.
35. MAILLARD I, ADLER SH, PEAR WS: Notch and the immune system. Immunity (2003) 19(6):781-791. A novel and very interesting approach to specific immunomodulation.
36. BOUSQUET J, LOCKEY FR, MALLING H-J: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. Allergy (1998) 53:1-42. A landmark paper providing ratification of AV as a mainstream method of treating allergy.
37. WILSON DR, TORRES LIMA M, DURHAM SR: Sublingual immunotherapy for allergic rhinitis (Cochrane Review). In: The Cochrane Library, issue 2 (2003). Oxford: Update software. A very thorough statistical analysis of controlled sublingual immunotherapy studies concludes that the treatment may be safe and efficacious.
38. KLIMEK L, STUCK B, HUNDORF J, SCHNEIDER-GENE S, HÖRMANN K: Monophosphoryl lipid A (MPL®) has Th1 stimulating properties in immunotherapy with birch pollen allergoid. Allergy (2001) 56(Suppl. 68):93. Provides good evidence of MPL inducing a ThI adjuvant effect.
39. ROVER AC, REIMANN S, ZUBERBIER T, WORM M: Immmunophenotypic characterization of peripheral B cells during short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. J. Invest. Allergol. Clin. Immunol. (2002) 12(4):227-234. Provides good evidence of MPL inducing a Th1 adjuvant effect.
40. VON BAEHR V, SCHERF HP, HERMES A: Allergoid-specific cellular immune response as a possible marker for immunological in vitro effects of immunotherapy. Allergy (2001) 56(Suppl.68):91. A publication supporting the use of allergoids, but with rather complex methodology.
41. PUGGIONI F, FRANCIS JN, DURHAM SR: Monophosphoryl lipid A: in vitro effects on human T cell proliferation and cytokine production. J. Allergy Clin. Immunol. (2003) 111(Pt2):333. Support for Th1 adjuvants from a prestigious group.